|0.6149 0.005 (0.8%)||11-29 10:01|
|Targets||6-month :||0.88||1-year :||1.03|
|Resists||First :||0.75||Second :||0.88|
|Supports||First :||0.56||Second :||0.44|
|MAs||MA(5) :||0.61||MA(20) :||0.61|
|MA(100) :||0.93||MA(250) :||5.88|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||33.5||D(3) :||30.8|
|52-week||High :||21||Low :||0.44|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VBIV ] has closed above bottom band by 42.5%. Bollinger Bands are 68.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||0.63 - 0.64||0.64 - 0.64|
|Low:||0.57 - 0.57||0.57 - 0.57|
|Close:||0.59 - 0.59||0.59 - 0.6|
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||23 (M)|
|Held by Insiders||2.044e+007 (%)|
|Held by Institutions||9.5 (%)|
|Shares Short||444 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-97.7 %|
|Return on Assets (ttm)||-29.5 %|
|Return on Equity (ttm)||-219.8 %|
|Qtrly Rev. Growth||1 %|
|Gross Profit (p.s.)||529.19|
|Sales Per Share||4.34225e+006|
|Qtrly Earnings Growth||-9.8 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-68 (M)|
|Price to Book value||0|
|Price to Sales||0|
|Price to Cash Flow||1.34|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|